{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"pt-141-metformin","title":"PT-141 × Metformin","body":"## PT-141 and metformin — where repair fits\nmetformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether pt-141 mechanisms address underlying repair deficits.\n\n## What is known about PT-141 with metformin\nStudied regenerative or supportive role in sexual / CNS arousal — see peptide root ledger.\n\nTarget condition: metformin.\nBody system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..\n\n## Logic chain — PT-141 to metformin\n1. pt-141 studied regenerative or supportive role in sexual / cns arousal — see peptide root ledger..\n2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.\n3. If pt-141 reaches the affected tissue, it may shift the repair/breakdown balance.\n4. This chain is under investigation.\n\n## PT-141 parent claims that bear on metformin\n- PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that activates central nervous system pathways for sexual arousal signaling.\n- In two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT), subcutaneous bremelanotide 1.75 mg as needed produced statistically significant increases in Female Sexual Function Index-desire domain scores and reductions in Female Sexual Distress Scale scores versus placebo in premenopausal women with hypoactive sexual desire disorder.\n- Bremelanotide received FDA approval in 2019 as Vyleesi for acquired generalized hypoactive sexual desire disorder in premenopausal women.\n- Animal studies show melanocortin receptor activation in hypothalamic regions linked to sexual behavior.\n- Commercial vendors and clinics market this compound (10 commercial/clinic sources catalogued) — marketing material, not evidence.\n\n## Evidence tier for PT-141 with metformin\nEvidence status unclear — research ongoing.\n\n## What we do not know about PT-141 with metformin\n- Whether pt-141 reaches metformin tissue at functional concentrations\n- Optimal dosing, route, and duration for this target\n- Interaction with standard-of-care treatments for metformin\n- Long-term safety profile in this population\n\n## Safety note\n\nAll peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.","hero":null,"images":[],"style":{},"tags":["peptide"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-metformin/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[],"sources":[],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T18:05:39.601Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"PT-141 × Metformin","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"290569be3da76576bac66d7a7b130c6ffc5f71adfa1022070f1ec6d26bb36f4b"}],"provenance":[{"ts":"2026-06-29T18:05:39.601Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"f2a0dc610bdac156a564a557917d4664e3e5bad6b0fa974c8cd24c91ae19a585"},{"ts":"2026-07-17T02:41:07.607Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-metformin","response":"15 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f2a0dc610bdac156a564a557917d4664e3e5bad6b0fa974c8cd24c91ae19a585","hash":"c7f44436844340d4798332fb5e1fe637d0f069e4ed9e1041cafa6f391d35ca01"}],"energy":{"passes":2,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":1,"owner":1},"head":"c7f44436844340d4798332fb5e1fe637d0f069e4ed9e1041cafa6f391d35ca01"},"posted_at":"2026-06-29T18:05:39.601Z","created_at":"2026-06-29T18:05:39.601Z","updated_at":"2026-08-08T04:22:51.492Z","machine":{"shape":"article.machine/v1","slug":"pt-141-metformin","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-metformin","json":"https://miscsubjects.com/api/articles/pt-141-metformin","bundle":"https://miscsubjects.com/api/articles/pt-141-metformin/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":0,"sources":0,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-metformin/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-metformin","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-metformin\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-metformin\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-metformin/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-metformin\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-metformin | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-metformin","json":"/api/articles/pt-141-metformin","markdown":"/api/articles/pt-141-metformin/bundle?format=markdown","skill":"/api/articles/pt-141-metformin/skill","topology":"/api/articles/pt-141-metformin/topology","versions":"/api/articles/pt-141-metformin/revisions","invocations":"/api/articles/pt-141-metformin/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-metformin","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"2d077e772fe0c12830d50a810eb29064c694c007816e311becba9cd41aed10c9","object":{"object_type":"article-object","identity":{"id":"article:pt-141-metformin","slug":"pt-141-metformin","title":"PT-141 × Metformin"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/pt-141-metformin","role":"explain","audience":"human"},"skill":{"route":"/api/articles/pt-141-metformin/skill","role":"direct behavior","audience":"model","content":"---\nname: pt-141-metformin\ndescription: Apply the PT-141 × Metformin article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# PT-141 × Metformin\n\nThis Skill is the behavioral expression of [the canonical article](/a/pt-141-metformin). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/pt-141-metformin.\n- Read claims and relationships at /api/articles/pt-141-metformin/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nPT-141 and metformin — where repair fits metformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether pt-141 mechanisms address underlying repair deficits. What is known \n\n## Representations\n\n- Human: /a/pt-141-metformin\n- JSON: /api/articles/pt-141-metformin\n- Relationships: /api/articles/pt-141-metformin/topology\n- History: /api/articles/pt-141-metformin/revisions\n"},"json":{"route":"/api/articles/pt-141-metformin","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/pt-141-metformin/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","pt","141","metformin"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/pt-141-metformin/invocations?status=success","failure_events":"/api/articles/pt-141-metformin/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"pt-141-metformin","title":"PT-141 × Metformin","body":"## PT-141 and metformin — where repair fits\nmetformin represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether pt-141 mechanisms address underlying repair deficits.\n\n## What is known about PT-141 with metformin\nStudied regenerative or supportive role in sexual / CNS arousal — see peptide root ledger.\n\nTarget condition: metformin.\nBody system: Metabolic tool; B12/mitochondrial concerns at chronic use — context dependent..\n\n## Logic chain — PT-141 to metformin\n1. pt-141 studied regenerative or supportive role in sexual / cns arousal — see peptide root ledger..\n2. metformin involves metabolic tool; b12/mitochondrial concerns at chronic use — context dependent. dysfunction.\n3. If pt-141 reaches the affected tissue, it may shift the repair/breakdown balance.\n4. This chain is under investigation.\n\n## PT-141 parent claims that bear on metformin\n- PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that activates central nervous system pathways for sexual arousal signaling.\n- In two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT), subcutaneous bremelanotide 1.75 mg as needed produced statistically significant increases in Female Sexual Function Index-desire domain scores and reductions in Female Sexual Distress Scale scores versus placebo in premenopausal women with hypoactive sexual desire disorder.\n- Bremelanotide received FDA approval in 2019 as Vyleesi for acquired generalized hypoactive sexual desire disorder in premenopausal women.\n- Animal studies show melanocortin receptor activation in hypothalamic regions linked to sexual behavior.\n- Commercial vendors and clinics market this compound (10 commercial/clinic sources catalogued) — marketing material, not evidence.\n\n## Evidence tier for PT-141 with metformin\nEvidence status unclear — research ongoing.\n\n## What we do not know about PT-141 with metformin\n- Whether pt-141 reaches metformin tissue at functional concentrations\n- Optimal dosing, route, and duration for this target\n- Interaction with standard-of-care treatments for metformin\n- Long-term safety profile in this population\n\n## Safety note\n\nAll peptide use for metformin is research-context only. Not medical advice. Consult a physician before any experimental compound.","hero":null,"images":[],"style":{},"tags":["peptide"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-metformin/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[],"sources":[],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T18:05:39.601Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"PT-141 × Metformin","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"290569be3da76576bac66d7a7b130c6ffc5f71adfa1022070f1ec6d26bb36f4b"}],"provenance":[{"ts":"2026-06-29T18:05:39.601Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"f2a0dc610bdac156a564a557917d4664e3e5bad6b0fa974c8cd24c91ae19a585"},{"ts":"2026-07-17T02:41:07.607Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-metformin","response":"15 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f2a0dc610bdac156a564a557917d4664e3e5bad6b0fa974c8cd24c91ae19a585","hash":"c7f44436844340d4798332fb5e1fe637d0f069e4ed9e1041cafa6f391d35ca01"}],"energy":{"passes":2,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":1,"owner":1},"head":"c7f44436844340d4798332fb5e1fe637d0f069e4ed9e1041cafa6f391d35ca01"},"posted_at":"2026-06-29T18:05:39.601Z","created_at":"2026-06-29T18:05:39.601Z","updated_at":"2026-08-08T04:22:51.492Z","machine":{"shape":"article.machine/v1","slug":"pt-141-metformin","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-metformin","json":"https://miscsubjects.com/api/articles/pt-141-metformin","bundle":"https://miscsubjects.com/api/articles/pt-141-metformin/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":0,"sources":0,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-metformin/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-metformin","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-metformin\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-metformin\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-metformin/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-metformin\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-metformin | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-metformin","json":"/api/articles/pt-141-metformin","markdown":"/api/articles/pt-141-metformin/bundle?format=markdown","skill":"/api/articles/pt-141-metformin/skill","topology":"/api/articles/pt-141-metformin/topology","versions":"/api/articles/pt-141-metformin/revisions","invocations":"/api/articles/pt-141-metformin/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-metformin","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"2d077e772fe0c12830d50a810eb29064c694c007816e311becba9cd41aed10c9"}}}